Blood-Glucose reduction in Type 2 Diabetes Patients when using two different DPP-4, alogliptin or sitagliptin during 52-week administratio
Phase 4
Recruiting
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000007487
- Lead Sponsor
- Biomedis International Ltd Study Management
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Not provided
Exclusion Criteria
1. Type 1 diabetes or secondary diabetes 2. Patients with severe infecious disease, operation planned or just after done, and/or serious externalinjyury 3. Other DPP-4 agents users on the enrollement 4. Insulin users 5. Pregnant and possible pregnant, or Lactation 6. AST or ALT 2.5 times or more of normalvalue 7. Serum creatinine2 mg/dL or more 8. Patients with old myocardial infarction, angina pectoris and/or stroke 9. Patients having history of hypersensitivity against study drugs 10.Inappropriate reasons on the enrollment that the physicians/investigators are judged
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction value of HbA1c level (JDS) at 12, 24, 36, 52 (terminal) if comparing with at 0 (enrolled)
- Secondary Outcome Measures
Name Time Method Fasting blood glucose Patient rate completed